Enriched Whey Improved MCI Scores—But We Don’t Know Why

A whey protein formula enriched with milk fat globule membrane (MFGM), taurine, and B vitamins improved cognitive test scores over 12 months in adults with mild cognitive impairment (MCI). That result deserves attention. It does not yet justify treating the formula—or any one of its ingredients—as a proven cognitive supplement.

The problem is attribution. The trial tested four potentially active elements at once: whey protein, MFGM, taurine, and B vitamins. It compared the blend with a 15 g/day placebo, but the published abstract does not describe the placebo's protein content or disclose the doses of the added ingredients. The researchers found a signal. Their design cannot tell us what produced it.

A statistically significant result with a narrow margin for clinical relevance

In a 2025 randomized controlled trial by Li et al., 107 older adults with MCI, average age 62.9 years, received either 15 g/day of the enriched whey powder or a placebo for 12 months. The primary outcome was the Montreal Cognitive Assessment (MoCA), a screening test of global cognition. The active group exceeded the control group by 1.81 MoCA points (95% confidence interval, 0.32 to 3.30), a statistically significant difference.

The group difference on the Digit Symbol Substitution Test, a secondary measure, was 2.72 points (95% CI, 0.20 to 5.23), also statistically significant. These are encouraging findings, especially because the intervention lasted a year rather than a few weeks.

Still, statistical significance answers a limited question: whether the observed difference is compatible with no difference under the study's statistical assumptions. It does not establish that the benefit was large enough to change daily life. A commonly cited minimally clinically important difference for MoCA in MCI is about 1.5 to 2.0 points. The observed 1.81-point advantage falls near that threshold, while its lower confidence-limit estimate—0.32 points—would be clinically trivial.

The control group also improved by 1.42 MoCA points over 12 months (95% CI, 0.36 to 2.48). Repeated cognitive testing can produce practice effects, and people selected because of relatively low scores can improve through regression toward their usual level. The 1.81-point result is the estimated advantage over that improvement, not a 1.81-point reversal of cognitive decline.

The formula bundles ingredients with very different evidence

B vitamins have the strongest independent case in this mixture, but even that case has an important condition. A 2025 metabolomics analysis from the VITACOG trial linked B-vitamin supplementation in MCI with lower homocysteine and slower brain atrophy. The analysis described plausible pathways involving homocysteine-related DNA damage, PARP activation, NAD+ depletion, and hippocampal neuron apoptosis.

VITACOG's benefit, however, was concentrated among participants whose baseline homocysteine exceeded 13 μmol/L. Li and colleagues did not report baseline homocysteine. That omission matters because a B-vitamin intervention aimed at correcting elevated homocysteine may help a biologically distinct subgroup without helping people whose homocysteine is already low. The trial cannot show whether such a subgroup drove the result.

Taurine has a weaker human evidence base for cognition. A 2025 systematic review and meta-analysis of randomized trials concluded that taurine's role in cognition remains controversial. That does not prove taurine had no role in the whey trial. It means the trial's positive result cannot reasonably be assigned to taurine on the basis of existing independent evidence.

MFGM is even earlier in the evidence chain. The rationale for including it came from the authors' previous mouse Alzheimer's model. Animal work can generate a useful hypothesis, but it cannot establish a treatment effect in people with MCI. No published human randomized trial has established cognitive benefit from MFGM in adults.

Whey itself may be part of the story

Whey protein is not an inert delivery vehicle. A 2023 meta-analysis of 12 randomized trials found that whey protein used during resistance exercise improved skeletal muscle mass and strength in older adults with sarcopenia. That review did not measure cognition, so it does not show that whey protects the brain.

It does show why the comparator matters. MCI often coexists with sarcopenia, and better muscle mass, strength, and metabolic health could plausibly affect cognitive performance indirectly. If the placebo contained no matched protein, then the active group received both the enrichment ingredients and a biologically active protein base. The abstract does not provide enough detail to resolve that question.

This is not a minor technical complaint. If whey was unmatched, the study cannot separate an effect of protein nutrition from an effect of MFGM, taurine, or B vitamins. If the placebo did contain matched protein, that would reduce this concern—but readers need the full trial report and protocol details to assess it.

Exercise has a deeper evidence base in MCI

The formula also enters a field where several non-drug interventions already have replicated support. A systematic review and meta-analysis of exercise training in adults over 60 with MCI found cognitive improvements across resistance, aerobic, and multimodal programs. A separate meta-analysis of walking interventions found benefits for cognition and mobility in people with MCI.

The 2025 EXERT randomized trial enrolled 296 adults with MCI and examined exercise, cognition, and Alzheimer's biomarkers. It also placed the nutritional result in context: pharmaceutical approaches intended to prevent or arrest cognitive decline in MCI have often disappointed. Exercise is not a magic trick, but it has been tested repeatedly across programs and populations. The enriched whey formula has one small trial.

Li et al. did not include an exercise co-intervention or report control of physical activity in the abstract. Differences in exercise behavior between groups could therefore contribute to the cognitive gap. More broadly, a network meta-analysis of nonpharmacological MCI interventions found substantial variation among interventions and studies. A single positive trial is a starting point, not a ranking.

What would make the finding more convincing?

A follow-up trial should match the placebo for protein and calories, disclose every ingredient dose, measure baseline homocysteine, and prespecify analyses for participants above and below the 13 μmol/L threshold. Ideally, it would also include ingredient-isolation arms: whey alone, whey plus B vitamins, whey plus MFGM, whey plus taurine, and the full formula. That design would cost more and answer far more.

Independent replication matters as well. This study tested a proprietary formula, and its MFGM rationale came from the same group's earlier animal work. A transparent protocol, complete reporting of dropouts and blinding procedures, conflict-of-interest disclosure, and replication by an unaffiliated research team would make the result easier to trust.

What to do now

For someone with MCI or elevated concern about cognitive aging, the most defensible actions are less exotic. Ask a clinician about homocysteine testing and whether folate, vitamin B6, and vitamin B12 are appropriate if it is elevated. Do not assume that a B-complex helps everyone equally, and do not self-treat a possible B12 deficiency without medical guidance.

Build a structured exercise habit that fits your health status. Aerobic activity, resistance training, and walking have a more established MCI evidence base than MFGM or taurine. Whey protein can also be reasonable for older adults who need help preserving muscle mass, particularly alongside resistance training, but cognitive benefit remains unproven.

The enriched whey trial found a real, statistically significant cognitive signal. It has not identified the active ingredient, established a clinically reliable effect size, or shown that the formula will work outside this small study.

That is enough reason to watch for replication. It is not enough reason to buy a proprietary cognitive whey powder for its MFGM or taurine content.